Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
Medicare decides against tighter management of HIV drugs

The Department of Health and Human Services will continue barring Medicare Part D plans from applying the drug utilization management tools prior authorization and step therapy for beneficiaries taking HIV antiretroviral drugs. A rule proposed in November 2018 would have permitted such practices. Gilead voiced opposition to the original proposal, saying physicians need to have the flexibility to prescribe the right medicines for patients.

Published
17 hours ago
From
BioPharma Dive
Republicans defend drug company in spotlight over HIV medication prices

Republican members of Congress defended Gilead, the leading manufacturer of HIV drugs in the U.S., during a testy hearing Thursday as Democrats blasted the company over the prices of its products.

Published
17 May 2019
From
The Hill
Trump Administration Caves To Pharma On Medicare Part D 'Protected Classes' Reform

The Trump administration has shelved a proposal that would have stymied egregious price hikes in the Medicare prescription drug program. It’s a major win for the drug industry, and a defeat for Trump’s goal of reducing drug prices.

Published
17 May 2019
From
Forbes
A Leading HIV Drug Is Way Overpriced in the U.S.

A House hearing over the price of Truvada shows a particularly glaring example of a rampant industry practice.

Published
17 May 2019
From
Bloomberg
Alexandria Ocasio-Cortez Tells Gilead CEO That ‘People Are Dying’ Because His Company Charges Nearly $2,000 For Drug That Sells For $8 In Australia

"I think it's important here that we notice that we the public, we the people, developed this drug. We paid for this drug, we led and developed all the patents to create PrEP [the commonly known name for Truvada] and then that patent has been privatized, despite the fact that the patent is owned by the public, who refused to enforce it," the representative said. “There’s no reason this should be $2,000 a month. People are dying because of it,” she added.

Published
17 May 2019
From
Newsweek
Gilead Sciences Statement On Inaccurate Reporting On Truvada®

Among multiple inaccuracies published in a New York Times editorial on May 13, assertions that taxpayer dollars funded the development of Truvada® (FTC/TDF) are incorrect.

Published
16 May 2019
From
Gilead press release
Gilead tries—and fails—to dodge lawsuit claiming it delayed safer HIV meds

Gilead Sciences has faced years of allegations that it sidelined its safer, next-gen HIV drugs to reap as much revenue as possible from the older generation before the new meds hit. And a federal judge has allowed one set of those allegations—filed by 140 patients from 31 states—to proceed.

Published
15 May 2019
From
Fierce Pharma
Gilead struck anti-competitive deals to bolster profits on an HIV drug, lawsuit says

In a bid to maintain its dominance in the HIV market, Gilead Sciences (GILD) allegedly conspired with other drug makers whose medicines were part of a so-called combination cocktail in order to block generic competition, according to a lawsuit filed by AIDS activists and two unions.

Published
15 May 2019
From
STAT
Statement on Gilead’s Announcement of PrEP Donation

Gilead’s donation is an acknowledgment that there is a huge issue with PrEP access in America, as in many parts of the world. We welcome this indication that the company grasps the gravity of the situation. However, we urgently need a lower price for all. It’s disappointing that even this small step has taken so long.

Published
14 May 2019
From
AVAC
A Million Americans Need This Drug. Trump’s Deal Won’t Help Enough of Them.

A donation of H.I.V.-prevention drugs from the pharmaceutical giant Gilead could benefit shareholders more than patients.

Published
14 May 2019
From
The New York Times (editorial)
← First12345...111Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.